These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9108453)

  • 1. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
    Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
    Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
    Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
    Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
    Vaidyanathan G; Alston KL; Bigner DD; Zalutsky MR
    Bioconjug Chem; 2006; 17(4):1085-92. PubMed ID: 16848419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
    Foulon CF; Welsh PC; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2001 Oct; 28(7):769-77. PubMed ID: 11578897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
    Schuster JM; Garg PK; Bigner DD; Zalutsky MR
    Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
    Zalutsky MR; Xu FJ; Yu Y; Foulon CF; Zhao XG; Slade SK; Affleck DJ; Bast RC
    Nucl Med Biol; 1999 Oct; 26(7):781-90. PubMed ID: 10628557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.